ENDO OPERATIONS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENDO OPERATIONS, and when can generic versions of ENDO OPERATIONS drugs launch?
ENDO OPERATIONS has two hundred and twenty-one approved drugs.
There are forty-one US patents protecting ENDO OPERATIONS drugs. There is one tentative approval on ENDO OPERATIONS drugs.
There are one hundred and nineteen patent family members on ENDO OPERATIONS drugs in forty countries and three hundred and fifty-three supplementary protection certificates in seventeen countries.
Summary for ENDO OPERATIONS
International Patents: | 119 |
US Patents: | 41 |
Tradenames: | 176 |
Ingredients: | 155 |
NDAs: | 221 |
Drugs and US Patents for ENDO OPERATIONS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Operations | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | TABLET;ORAL | 203836-001 | Aug 19, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Endo Operations | QUETIAPINE FUMARATE | quetiapine fumarate | TABLET, EXTENDED RELEASE;ORAL | 090482-002 | May 9, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Endo Operations | LAMOTRIGINE | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 201374-002 | Dec 26, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Endo Operations | LAMOTRIGINE | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 201374-004 | Dec 26, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Endo Operations | SODIUM PHENYLBUTYRATE | sodium phenylbutyrate | TABLET;ORAL | 204395-001 | Apr 15, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Endo Operations | OXYCODONE AND ACETAMINOPHEN | acetaminophen; oxycodone hydrochloride | TABLET;ORAL | 040105-001 | Jul 30, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENDO OPERATIONS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Operations | FORTESTA | testosterone | GEL, METERED;TRANSDERMAL | 021463-001 | Dec 29, 2010 | 6,319,913 | ⤷ Sign Up |
Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-001 | Jun 22, 2006 | 8,329,216 | ⤷ Sign Up |
Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | 8,118,771 | ⤷ Sign Up |
Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | 5,891,086 | ⤷ Sign Up |
Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-002 | Jun 22, 2006 | 5,662,933 | ⤷ Sign Up |
Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-007 | Feb 29, 2008 | 5,128,143 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO OPERATIONS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 20 units/mL, 1 mL | ➤ Subscribe | 2018-03-23 |
➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-05-29 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2011-03-09 |
➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
➤ Subscribe | Gel | 1% | ➤ Subscribe | 2008-08-21 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Injection | 1 mg/mL ampules | ➤ Subscribe | 2016-03-09 |
➤ Subscribe | Extended-release Tablets | 5 mg, 10 mg, 20 mg and 40 mg | ➤ Subscribe | 2007-11-23 |
➤ Subscribe | Extended-release Tablets | 30 mg | ➤ Subscribe | 2008-06-12 |
➤ Subscribe | Gel | 10 mg/actuation | ➤ Subscribe | 2012-08-14 |
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Injection | 250 mg/mL | ➤ Subscribe | 2014-06-11 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for ENDO OPERATIONS Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2508301 | ⤷ Sign Up |
European Patent Office | 1689465 | ⤷ Sign Up |
Australia | 2007224221 | ⤷ Sign Up |
Canada | 2546468 | ⤷ Sign Up |
European Patent Office | 3268045 | ⤷ Sign Up |
China | 101242810 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ENDO OPERATIONS Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2380576 | SPC/GB20/050 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; REGISTERED: UK PL 45496/0009 20170526 |
3342411 | 122020000008 | Germany | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: EU/1/09/538/001-008 20110824 |
1441735 | 2008/010 | Ireland | ⤷ Sign Up | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
0268956 | SPC/GB98/040 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 |
2269604 | 132016000127697 | Italy | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/538/001-006, 20090805 |
3143995 | 34/2019 | Austria | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538 IDF DER ENTSCHEIDUNG DER KOMMISSION C (2016) 3286 (MITTEILUNG) 20160530 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.